title: Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction.
abstract: OBJECTIVE
  There are conflicting results regarding the impact of type 2 diabetes on intravenous thrombolysis effectiveness during ST elevation myocardial infarction (STEMI). The present study, using a continuous 12-lead electrocardiogram, examined the possible association of type 2 diabetes with both acute intravenous thrombolysis effectiveness and long-term prognosis in this setting.
  
  
  METHODS
  The study included 726 consecutive subjects (214 type 2 diabetic subjects) with STEMI who received intravenous thrombolysis in the first 6 h from index pain and were followed up for 3.5 years.
  
  
  RESULTS
  Type 2 diabetic subjects had significantly lower incidence of sustained > or = 50% ST recovery than nondiabetic subjects (P = 0.03). Additionally, the former required a significantly greater time interval through the achievement of this criterion than the latter (P < 0.001). In both type 2 diabetic (P < 0.001) and nondiabetic subjects (P < 0.001), those who had not attained > or = 50% ST recovery were at significantly higher risk of cardiac death than subjects who had reached this criterion. The subjects who attained the above electrocardiographic criterion in > or = 60 min after thrombolysis initiation were at significantly higher risk compared with those who achieved this criterion in <60 min (P = 0.02). However, this association was true only for type 2 diabetic subjects (P = 0.01) and not for nondiabetic subjects (P = 0.9).
  
  
  CONCLUSIONS
  The present study suggests that type 2 diabetes is a strong predictor of acute intravenous thrombolysis failure during STEMI. This finding may significantly contribute to the worse prognosis for type 2 diabetic subjects compared with nondiabetic ones in this setting.
authors.affiliation: Department of Cardiology, Tzanio Hospital, Piraeus, Greece. zairis@hellasnet.gr
authors.forename: Michael N
authors.initials: MN
authors.lastname: Zairis
authors.forename: Anastassios G
authors.initials: AG
authors.lastname: Lyras
authors.forename: Stamatis S
authors.initials: SS
authors.lastname: Makrygiannis
authors.forename: Paraskevi K
authors.initials: PK
authors.lastname: Psarogianni
authors.forename: Evdokia N
authors.initials: EN
authors.lastname: Adamopoulou
authors.forename: Stelios M
authors.initials: SM
authors.lastname: Handanis
authors.forename: Apostolos
authors.initials: A
authors.lastname: Papantonakos
authors.forename: Spyros K
authors.initials: SK
authors.lastname: Argyrakis
authors.forename: Athanasios A
authors.initials: AA
authors.lastname: Prekates
authors.forename: Stefanos G
authors.initials: SG
authors.lastname: Foussas
mesh_terms: D000368:Aged; D015331:Cohort Studies; D003643:Death; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D011446:Prospective Studies; D020127:Recovery of Function; D012306:Risk; D016037:Single-Blind Method; D013300:Streptokinase / Q000008:administration & dosage; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator